Bufalin suppresses ovarian cancer cell proliferation via EGFR pathway

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Bufalin, derived from traditional Chinese medicine toad venom, exhibits known antitumor properties.
• Ovarian cancer remains a significant health concern, necessitating novel therapeutic strategies.
• Understanding bufalin's specific antineoplastic mechanisms is crucial for its clinical application.

Purpose of the Study:

• To investigate the antineoplastic mechanism of bufalin in ovarian cancer.
• To determine bufalin's effect on ovarian cancer cell proliferation and its molecular targets.
• To elucidate the role of the epidermal growth factor receptor (EGFR) signaling pathway in bufalin's action.

Main Methods:

• Utilized MTT, EdU, and colony formation assays to assess bufalin's antiproliferative effects on the SK-OV-3 ovarian cancer cell line.
• Employed molecular docking to examine the interaction between bufalin and epidermal growth factor receptor (EGFR) protein.
• Conducted Western blotting to analyze the expression of EGFR and its downstream signaling molecules.

Main Results:

• Bufalin demonstrated a dose- and time-dependent inhibition of SK-OV-3 cell proliferation.
• Molecular docking confirmed bufalin's binding to EGFR, leading to downregulated EGFR expression.
• Bufalin significantly inhibited the phosphorylation of EGFR, protein kinase B (AKT), and extracellular signal-regulated kinase (ERK).

Conclusions:

• Bufalin effectively suppresses ovarian cancer cell proliferation.
• The antineoplastic effect of bufalin is mediated through the inhibition of the EGFR/AKT/ERK signaling pathway.
• Bufalin represents a potential therapeutic agent for ovarian cancer, warranting further investigation.